These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25043962)

  • 1. The future of antibiotics.
    Spellberg B
    Crit Care; 2014 Jun; 18(3):228. PubMed ID: 25043962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE; Morel CM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [No Abstract]   [Full Text] [Related]  

  • 5. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections.
    Hwang TJ; Kesselheim AS
    Am J Law Med; 2016 May; 42(2-3):429-450. PubMed ID: 29086648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.
    Rex JH; Eisenstein BI; Alder J; Goldberger M; Meyer R; Dane A; Friedland I; Knirsch C; Sanhai WR; Tomayko J; Lancaster C; Jackson J
    Lancet Infect Dis; 2013 Mar; 13(3):269-75. PubMed ID: 23332713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The global challenge of new classes of antibacterial agents: an industry perspective.
    Fernandes P
    Curr Opin Pharmacol; 2015 Oct; 24():7-11. PubMed ID: 26119487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR;
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platforms for antibiotic discovery.
    Lewis K
    Nat Rev Drug Discov; 2013 May; 12(5):371-87. PubMed ID: 23629505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
    Brogan DM; Mossialos E
    Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate antibiotic use and why it is important: the challenges of bacterial resistance.
    Lieberman JM
    Pediatr Infect Dis J; 2003 Dec; 22(12):1143-51. PubMed ID: 14688589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Market power in the United States red meatpacking industry.
    Koontz SR
    Vet Clin North Am Food Anim Pract; 2003 Jul; 19(2):519-44. PubMed ID: 12951745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?
    Talbot GH; Jezek A; Murray BE; Jones RN; Ebright RH; Nau GJ; Rodvold KA; Newland JG; Boucher HW;
    Clin Infect Dis; 2019 Jun; 69(1):1-11. PubMed ID: 30715222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renaissance in Antibiotic Discovery: Some Novel Approaches for Finding Drugs to Treat Bad Bugs.
    Gadakh B; Van Aerschot A
    Curr Med Chem; 2015; 22(18):2140-58. PubMed ID: 25787965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antibiotic's journey from marketing authorization to use, Norway.
    Årdal C; Blix HS; Plahte J; Røttingen JA
    Bull World Health Organ; 2017 Mar; 95(3):220-226. PubMed ID: 28250535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.